Allos Therapeutics hits 52-week high after advancing bladder cancer study

Tweet   

Biopharmaceutical company Allos Therapeutics Inc. (Nasdaq:ALTH) said before the opening today it had started its phase two study of its drug pralatrexate in patients with advanced or metastatic cancer of the urinary bladder. The news pushed shares up 10% to a 52-week high for the Westminster, Colo.-based company.

In today’s trading, shares are at $8.91 at 12:09 p.m. ET, up $0.76 from Friday’s close. Trading volume is more than 100,000 shares above average.

For detailed price information and recent news stories about Allos Therapeutics Inc., click ALTH.